A Review on Adverse Drug Reaction Management

Jayshree k. bakal[1], Shankar S Khandare[1]
[1]*RaosahebPatil Danve College of Pharmacy Badnapur, Jalna, Maharashtra*

Abstract- Adverse drug reactions (ADRs) remain a major concern for patient safety and public health, contributing significantly to morbidity, mortality, and rising healthcare costs worldwide. Although medicines undergo extensive preclinical and clinical evaluation prior to approval, many ADRs become evident only after widespread use in real-world clinical practice. Therefore, effective management of ADRs is essential to ensure the safe, rational, and effective use of medications. ADR management involves the systematic detection, assessment, treatment, prevention, and reporting of adverse drug events through organized pharmacovigilance systems. This review presents an overview of current concepts and practices in ADR management, highlighting both traditional and emerging strategies. Spontaneous reporting systems continue to form the backbone of ADR detection; however, their effectiveness is limited by underreporting, incomplete information, and reporting bias. To overcome these challenges, active surveillance approaches utilizing real-world data sources such as electronic health records, insurance claims databases, and patient registries are increasingly employed to enhance signal detection and safety monitoring. Causality assessment tools, including the WHO–UMC scale and Naranjo's algorithm, play a crucial role in the systematic evaluation of suspected ADRs and support informed clinical decision-making. The review also emphasizes the vital role of healthcare professionals—particularly physicians, pharmacists, and nurses—in identifying, managing, and preventing ADRs through interdisciplinary collaboration and patient education. Furthermore, regulatory frameworks, post-marketing surveillance, and risk management plans are essential for translating safety signals into effective risk-minimization strategies. Recent advances in artificial intelligence, machine learning, and pharmacogenomics offer promising opportunities for improving early detection and prevention of ADRs, despite ongoing challenges related to data quality and implementation. Overall, effective ADR management requires a comprehensive, multidisciplinary, and proactive approach to improve medication safety and therapeutic outcomes.

I.INTRODUCTION

India is among the 22 high tuberculosis (TB) burden countries worldwide and accounts for approximately one-quarter (26%) of the global TB cases. The standard treatment for drug-susceptible tuberculosis (DSTB) relies on a multidrug regimen comprising first-line anti-tubercular drugs (FLDs), including isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E), and streptomycin (S). Second-line drugs (SLDs) are primarily reserved for the management of drug-resistant tuberculosis (DR-TB). Successful TB treatment depends largely on two critical factors: accurate bacteriological diagnosis and strict adherence to the prescribed treatment regimen.[1] The World Health Organization (WHO) defines an adverse drug reaction (ADR) as "a response to a drug which is noxious and unintended, and which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function." Patients receiving anti-tubercular therapy frequently experience a wide range of ADRs. In addition, treatment may be associated with adverse events, defined as any untoward medical occurrence that does not necessarily have a causal relationship with drug therapy. ADRs related to anti-tubercular drugs are common and can result in significant morbidity and, in some cases, mortality if not detected and managed promptly.[2] Although the majority of ADRs are mild and can be managed without discontinuation of therapy, some reactions may be severe or life-threatening, leading to prolonged hospitalization, significant disability, congenital anomalies, or death if unrecognized. The timing of onset, clinical presentation, laboratory findings, and response to drug rechallenge are important factors in establishing causality. Several patient-related and treatment-related factors—such as drug dose, timing of administration, age, nutritional status, pre-existing liver or renal dysfunction, HIV co-infection, and

alcoholism—increase the risk of ADRs. Therefore, continuous pharmacovigilance and early recognition of ADRs, particularly among patients with DR-TB, are essential to ensure favorable treatment outcomes. This review aims to highlight the burden and management strategies of ADRs associated with anti-tubercular drugs in patients undergoing TB treatment.[3]

Figure 1: Adverse Drug Reaction (ADR) Management



II.PHARMACOVIGILANCE AND ADVERSE DRUG REACTION (ADR) MANAGEMENT

Pharmacovigilance is a vital component of modern healthcare systems, aimed at ensuring the safe and effective use of medicines. The World Health Organization (WHO) defines pharmacovigilance as *"the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problems"* [4]. This discipline plays a central role in safeguarding patient health, improving therapeutic outcomes, and supporting rational drug use.

Adverse drug reactions (ADRs) are among the most significant medicine-related problems encountered in clinical practice and public health programs. ADR management is an integral and core component of pharmacovigilance, involving a structured process to identify suspected reactions, assess their causality and severity, manage the clinical consequences, and prevent recurrence [5]. Effective ADR management reduces morbidity and mortality, enhances patient compliance, and improves overall quality of care.

The process of ADR management begins with early detection, which may occur through spontaneous reporting by healthcare professionals, active surveillance, patient self-reports, or routine clinical monitoring [6]. Once an ADR is suspected, a detailed assessment is performed to establish a causal relationship between the drug and the adverse event. Standardized tools such as the WHO-UMC causality assessment scale are widely used to ensure consistency and reliability in evaluation [7].

After assessment, appropriate management strategies are implemented. These may include dose modification, temporary or permanent discontinuation of the suspected drug, substitution with an alternative therapy, or symptomatic treatment of the reaction [8]. In cases of serious or life-threatening ADRs, immediate medical intervention and hospitalization may be required. All confirmed or suspected ADRs should be properly documented and reported to pharmacovigilance centers, contributing to national and global drug safety databases [9].

Understanding ADR patterns and risk factors enables pharmacovigilance systems to implement preventive and risk-minimization measures, such as safety alerts, label changes, treatment guideline revisions, and education of healthcare professionals and patients [10]. Pharmacovigilance is particularly crucial in long-term and multidrug therapies, such as tuberculosis treatment, where the risk of ADRs is high and patient adherence is essential for treatment success [11].

III.COMMON DATA SOURCES AND SURVEILLANCE APPROACHES

Pharmacovigilance utilizes multiple data sources and surveillance approaches to ensure effective detection, assessment, and prevention of adverse drug reactions (ADRs) in real-world clinical practice. The integration of these systems supports early signal detection, risk evaluation, and regulatory decision-making [11].

3.1 Spontaneous Reporting Systems (SRS)

Spontaneous reporting systems form the foundation of global pharmacovigilance. They rely on voluntary reporting of suspected ADRs by healthcare professionals, patients, and pharmaceutical companies to national and international pharmacovigilance centers. Major examples include the WHO

Programme for International Drug Monitoring coordinated by the Uppsala Monitoring Centre and the Pharmacovigilance Programme of India (PvPI) [12]. Despite their effectiveness in identifying rare and unexpected ADRs, SRS are limited by under-reporting and reporting bias [13].

3.2 Active Surveillance Systems

Active surveillance involves systematic and proactive collection of ADR data through structured methodologies such as cohort event monitoring, prescription event monitoring, and targeted follow-up of patients [14]. This approach enables estimation of ADR incidence and identification of risk factors, making it particularly valuable for newly marketed medicines and public health programs [15].

3.3 Electronic Health Records and Medical Databases

Electronic health records (EHRs), hospital databases, and insurance claims databases serve as important real-world data sources for pharmacovigilance. These systems allow continuous safety monitoring and facilitate automated signal detection using data-mining and statistical algorithms [16]. However, challenges related to data completeness, coding accuracy, and confounding factors remain significant [17].

3.4 Clinical Trials and Post-Marketing Studies

Safety data generated from pre-marketing clinical trials and post-authorization safety studies contribute substantially to pharmacovigilance. While clinical trials provide controlled safety information, their limited sample size and duration often restrict detection of rare or delayed ADRs [18]. Post-marketing surveillance studies help overcome these limitations by evaluating drug safety in broader patient populations [19].

3.5 Registries and Sentinel Surveillance

Disease-specific registries, drug exposure registries, and sentinel surveillance sites systematically collect long-term safety data. These systems are particularly useful for monitoring ADRs in special populations such as pregnant women, pediatric patients, and individuals receiving long-term therapy [20].

3.6 Pharmacovigilance in Public Health Programs

In large-scale public health programs, including tuberculosis, HIV/AIDS, and immunization initiatives, pharmacovigilance is integrated into routine healthcare delivery. Targeted surveillance approaches are essential for monitoring ADRs associated with prolonged treatment regimens and polypharmacy, thereby improving patient safety and treatment adherence [21].

In summary, the combined use of passive and active surveillance methods, supported by diverse data sources, strengthens pharmacovigilance systems and enhances the effective management and prevention of ADRs.

Figure 2: Adverse Drug Reaction (ADR) Management

IV.SIGNAL DETECTION AND ANALYTICAL METHODS

Signal detection is a fundamental activity in pharmacovigilance aimed at identifying new, rare, or previously unrecognized adverse drug reactions (ADRs), as well as changes in the frequency or severity of known reactions. A *signal* is defined as information that arises from one or multiple sources and suggests a new potentially causal association between a drug and an adverse event that warrants further investigation [22].

4.1 Sources of Signals

Signals may originate from a variety of data sources, including spontaneous reporting systems, clinical trials, observational studies, electronic health records, and scientific literature [23]. Among these, spontaneous reporting databases remain the primary source for early signal detection due to their wide coverage and ability to capture rare and unexpected ADRs [24].

4.2 Qualitative Signal Detection Methods

Qualitative methods rely on clinical judgment and expert review of individual case safety reports (ICSRs). These approaches involve case series evaluation, medical review, temporal relationship assessment, biological plausibility analysis, and comparison with existing literature [25]. Although subjective, qualitative methods are essential for contextualizing signals and guiding subsequent quantitative analysis.

4.3 Quantitative (Statistical) Signal Detection Methods

Quantitative methods utilize statistical and data-mining techniques to identify disproportionate reporting of specific drug–event combinations in large pharmacovigilance databases. Commonly used measures include the Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM) [26]. These techniques help prioritize signals by highlighting associations reported more frequently than expected.

4.4 Data Mining and Artificial Intelligence Approaches

Advances in computational science have enhanced signal detection through machine learning, artificial intelligence (AI), and natural language processing (NLP). These methods improve pattern recognition, handle large datasets efficiently, and reduce false-positive signals [27]. AI-based approaches are increasingly applied to real-world data sources such as electronic health records and social media platforms [28].

4.5 Signal Validation and Assessment

Detected signals must undergo rigorous validation to confirm their clinical relevance. Signal assessment includes evaluation of causality, strength and consistency of association, dose–response relationship, temporal association, and biological plausibility [29]. Regulatory authorities may request additional epidemiological studies or post-authorization safety studies to confirm or refute the signal.

4.6 Regulatory Decision-Making

Once a signal is confirmed, appropriate regulatory actions may be initiated. These actions include updates to product labeling, issuance of safety alerts, restriction of drug use, implementation of risk minimization measures, or withdrawal of the drug from the market in severe cases [30]. Continuous monitoring ensures that benefit–risk balance remains favorable throughout a drug's lifecycle.

In summary, signal detection and analytical methods form the scientific backbone of pharmacovigilance. The combined use of qualitative assessment, statistical analysis, and advanced computational techniques enables early identification of safety concerns and supports evidence-based regulatory decision-making.

V. REGULATORY FRAMEWORKS AND MANAGEMENT TOOLS

Regulatory frameworks play a crucial role in pharmacovigilance by establishing legal, organizational, and procedural requirements for monitoring the safety of medicinal products throughout their lifecycle. These frameworks ensure systematic detection, assessment, reporting, and management of adverse drug reactions (ADRs), thereby protecting public health and supporting rational medicine use [31].

5.1 International Regulatory Frameworks

At the global level, the World Health Organization (WHO) provides guidance and coordination through the Programme for International Drug Monitoring (PIDM), which facilitates global sharing of safety data via the VigiBase database maintained by the Uppsala Monitoring Centre [32]. International standards developed by the International Council for Harmonisation (ICH), particularly ICH E2A–E2F guidelines, define requirements for expedited reporting, periodic safety update reports (PSURs), and pharmacovigilance planning [33].

5.2 Regional and National Regulatory Systems

Regional regulatory authorities such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) have established comprehensive pharmacovigilance regulations. In the European Union, Good Pharmacovigilance Practices (GVP) provide a structured framework for signal

management, risk assessment, and risk minimization activities [34]. In India, pharmacovigilance activities are coordinated through the Pharmacovigilance Programme of India (PvPI) under the Central Drugs Standard Control Organization (CDSCO), which oversees ADR reporting and safety monitoring nationwide [35].

5.3 Pharmacovigilance Management Tools

Several tools are employed to implement regulatory requirements effectively. These include Individual Case Safety Reports (ICSRs), Periodic Safety Update Reports (PSURs), Risk Management Plans (RMPs), and Post-Authorization Safety Studies (PASS) [36]. These tools support continuous benefit–risk evaluation and enable timely regulatory action when safety concerns arise.

5.4 Risk Minimization and Communication Tools

Risk minimization measures are critical management tools designed to prevent or reduce the occurrence and severity of ADRs. These measures include labeling updates, restricted prescribing programs, educational materials for healthcare professionals and patients, medication guides, and direct healthcare professional communications (DHPCs) [37]. Transparent and timely risk communication enhances awareness and promotes safe medicine use.

5.5 Pharmacovigilance Audits and Inspections

Regulatory authorities conduct routine pharmacovigilance audits and inspections to ensure compliance with established regulations. These activities assess the effectiveness of pharmacovigilance systems, data quality, and adherence to reporting timelines [38]. Non-compliance may result in regulatory actions such as warning letters, fines, or suspension of marketing authorization.

VI.EMERGING TRENDS IN ADVERSE DRUG REACTION (ADR) MANAGEMENT

The field of adverse drug reaction (ADR) management is rapidly evolving due to advancements in digital health technologies, data science, and patient-centered care models. Emerging trends aim to enhance early detection, improve risk prediction, and strengthen prevention strategies, thereby improving overall medication safety [39].

6.1 Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) are increasingly applied to pharmacovigilance for automated signal detection, causality assessment, and prediction of ADR risk. These technologies enable analysis of large and complex datasets from spontaneous reporting systems, electronic health records, and real-world evidence sources, improving efficiency and accuracy in ADR identification [40].

6.2 Real-World Evidence and Big Data Analytics

The use of real-world evidence (RWE) derived from electronic health records, insurance claims, patient registries, and observational studies has expanded significantly. Big data analytics allows continuous safety monitoring across diverse populations, enabling earlier identification of rare, long-term, or population-specific ADRs that may not be detected in clinical trials [41].

6.3 Pharmacogenomics and Personalized Medicine

Pharmacogenomic approaches are transforming ADR management by identifying genetic factors that influence drug response and susceptibility to adverse reactions. Genetic testing can help predict patient-specific ADR risk and guide individualized therapy, reducing the likelihood of serious drug-related harm [42].

6.4 Patient-Centered and Direct Patient Reporting

Modern pharmacovigilance systems increasingly emphasize patient involvement through direct ADR reporting via mobile applications, online portals, and social media platforms. Patient-reported outcomes provide valuable insights into real-world drug safety and enhance detection of ADRs affecting quality of life [43].

6.5 Digital Health Tools and Mobile Technologies

Mobile health (mHealth) applications, wearable devices, and telemedicine platforms support real-time monitoring of drug safety and patient adherence. These tools facilitate timely detection and management of ADRs, particularly in chronic disease management and long-term therapies [44].

6.6 Global Collaboration and Regulatory Harmonization

Enhanced international collaboration and regulatory harmonization are improving global ADR management. Initiatives by WHO, ICH, and regional regulatory agencies promote standardized reporting, shared databases, and coordinated safety actions across countries, strengthening global drug safety surveillance [45].

VII.DISCUSSION

Adverse drug reactions (ADRs) remain a major challenge to patient safety and healthcare systems worldwide. Despite significant advancements in pharmacotherapy, ADRs continue to contribute substantially to patient morbidity, mortality, and increased healthcare costs. This review highlights that effective ADR management is not limited to detection alone but requires an integrated framework encompassing pharmacovigilance, regulatory oversight, analytical methodologies, and emerging technological innovations.

One of the key observations from this review is that pharmacovigilance forms the foundation of ADR management. Spontaneous reporting systems remain the most widely used method for identifying rare and unexpected ADRs; however, under-reporting and reporting bias significantly limit their effectiveness. This emphasizes the need for complementary surveillance approaches, including active monitoring systems and the use of real-world data, to improve signal detection and risk assessment accuracy.

The discussion also underscores the importance of signal detection and analytical methods in modern pharmacovigilance. Traditional qualitative assessment based on clinical judgment continues to play a critical role in contextualizing safety signals. However, the increasing volume of safety data necessitates the adoption of quantitative and data-mining approaches such as disproportionality analysis and Bayesian methods. These tools enhance early detection of potential safety concerns but require careful interpretation to avoid false-positive signals.

Regulatory frameworks and management tools were found to be central to translating pharmacovigilance data into actionable safety measures. International harmonization through organizations such as the WHO, ICH, and regional regulatory agencies has improved consistency in ADR reporting, risk assessment, and communication. Tools such as Periodic Safety Update Reports, Risk Management Plans, and post-authorization safety studies enable continuous benefit–risk evaluation throughout a drug's lifecycle. However, variability in implementation across countries remains a challenge, particularly in resource-limited settings.

Emerging trends discussed in this review demonstrate a paradigm shift in ADR management. The integration of artificial intelligence, machine learning, and big data analytics offers promising solutions for overcoming limitations of traditional pharmacovigilance systems. Additionally, pharmacogenomics introduces a personalized approach to ADR prevention by identifying genetically susceptible individuals. Increased patient involvement through direct ADR reporting and digital health technologies further strengthens real-time safety monitoring and patient engagement.

Despite these advancements, several challenges persist, including data quality issues, lack of awareness among healthcare professionals and patients, and limited infrastructure in developing regions. Strengthening training programs, promoting a culture of safety reporting, and enhancing global collaboration are essential to address these gaps.

In conclusion, ADR management is a dynamic and evolving discipline that requires a multidisciplinary and technology-driven approach. The findings of this review suggest that integrating traditional pharmacovigilance practices with advanced analytical tools, robust regulatory frameworks, and emerging digital innovations can significantly enhance medication safety and improve therapeutic outcomes. Future efforts should focus on strengthening global harmonization.

VIII.CONCLUSION

Adverse drug reaction (ADR) management is a critical component of patient safety and rational drug use in modern healthcare. This review highlights that effective ADR management extends beyond the mere identification of adverse events and requires a comprehensive, multidisciplinary approach encompassing pharmacovigilance systems, robust regulatory frameworks, advanced analytical methods, and emerging digital technologies.

Traditional pharmacovigilance practices, including spontaneous reporting and active surveillance, continue to play a vital role in detecting and monitoring ADRs. However, their effectiveness is significantly enhanced when integrated with real-world evidence, data-mining techniques, and artificial intelligence-based tools. Regulatory mechanisms such as risk management plans, periodic safety update reports, and post-marketing surveillance ensure continuous benefit–risk evaluation throughout the lifecycle of medicinal products.

Emerging trends, including pharmacogenomics, patient-centered reporting, and digital health innovations, represent a paradigm shift toward personalized and proactive ADR management. These advancements have the potential to improve early detection, minimize preventable ADRs, and enhance therapeutic outcomes. Nevertheless, challenges such as under-reporting, limited awareness, and variability in implementation across healthcare systems persist and must be addressed through education, capacity building, and global collaboration.

In conclusion, strengthening ADR management through integrated pharmacovigilance strategies, technological innovation, and regulatory harmonization is essential for improving medication safety and public health. Continued efforts toward developing patient-centric, data-driven, and globally coordinated pharmacovigilance systems will play a key role in reducing drug-related harm and ensuring safer therapeutic practices in the future.

ACKNOWLEDGEMENT

The authors would like to express their sincere gratitude to the faculty and management of Raosaheb Patil Danve College of Pharmacy, Badnapur, for providing the necessary academic support and facilities to carry out this review work.

REFERENCES

[1] *Forget EJ, Menzies D. Adverse reactions to first-line anti tuberculosis drugs. Expert Opin Drug Saf. 2006; 5:231e249*

[2] *World Health Organization. Global Tuberculosis Report 2018. Geneva: WHO; 2018, 2018WHO/CDS/TB/2018.20.*

[3] *World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. WHO Press, Geneva; 2002.*

[4] *Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–1259.*

[5] *Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002. Arch Intern Med. 2005;165:1363–1369.*

[6] *World Health Organization–Uppsala Monitoring Centre. The WHO-UMC System for Standardised Case Causality Assessment. UMC, Sweden; 2005.*

[7] *Pirmohamed M et al. Adverse drug reactions as cause of admission to hospital: prospective analysis. BMJ. 2004;329:15–19.*

[8] *Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf. 2006;29:385–396.*

[9] *Arora D, et al. Pharmacovigilance: a review. Int J Pharm Sci Res. 2015;6(11):4550–4558.*

[10] *Tostmann A et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192–202.*

[11] *World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva: WHO; 2002.*

[12] *World Health Organization–Uppsala Monitoring Centre. WHO Programme for International Drug Monitoring. UMC, Sweden; 2020.*

[13] *Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf. 2006;29:385–396.*

[14] *Mann RD, Andrews EB. Pharmacovigilance. 2nd ed. Chichester: Wiley; 2007.*

[15] *15.Coulter DM. Monitoring medicine safety: the role of cohort event monitoring. Pharmacoepidemiol Drug Saf. 2011;20:116–123.*

[16] *Harpaz R, et al. Performance of pharmacovigilance signal-detection algorithms. Clin Pharmacol Ther. 2012;91:1014–1021.*

[17] *Schneeweiss S, Avorn J. Uses of health care utilization databases for epidemiologic research. J Clin Epidemiol. 2005;58:323–337.*

[18] *Ioannidis JPA. Publication and completion of randomized efficacy trials. JAMA. 1998;279:281–286.*

[19] *Giezen TJ, et al. Post-authorization safety studies in the EU. Drug Saf. 2009;32:223–234.*

[20] *Dreyer NA, et al. Registries for robust evidence generation. Pharmacoepidemiol Drug Saf. 2012;21:1005–1014.*
[21] *World Health Organization. A Practical Handbook on the Pharmacovigilance of Medicines Used in the Treatment of Tuberculosis. Geneva: WHO; 2012.*
[22] *World Health Organization. Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre. Geneva: WHO; 2000.*
[23] *Meyboom RHB, et al. Signal detection in pharmacovigilance. Drug Saf. 1997;16:355–365.*
[24] *Edwards IR. Spontaneous reporting—strengths and weaknesses. Drug Saf. 1998;18:343–350.*
[25] *Hauben M, Aronson JK. Defining 'signal' in pharmacovigilance. Drug Saf. 2009;32:99–110.*
[26] *Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios. Pharmacoepidemiol Drug Saf. 2001;10:483–486.*
[27] *Harpaz R, et al. Data mining for adverse drug events. Clin Pharmacol Ther. 2012;91:1014–1021.*
[28] *Sarker A, et al. Utilizing social media data for pharmacovigilance. J Biomed Inform. 2015;54:202–212.*
[29] *CIOMS Working Group VIII. Practical Aspects of Signal Detection in Pharmacovigilance. Geneva: CIOMS; 2010.*
[30] *European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP): Module IX—Signal Management. EMA; 2017.*
[31] *World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva: WHO; 2002.*
[32] *World Health Organization–Uppsala Monitoring Centre. WHO Programme for International Drug Monitoring. UMC, Sweden; 2020.*
[33] *International Council for Harmonisation (ICH). Clinical Safety Data Management Guidelines (E2A–E2F). ICH; 2016.*
[34] *European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP). EMA; 2017.*
[35] *Central Drugs Standard Control Organization (CDSCO). Pharmacovigilance Programme of India (PvPI). Ministry of Health and Family Welfare, Government of India; 2020.*
[36] *Giezen TJ, et al. Post-authorization safety studies. Drug Saf. 2009;32:223–234.*
[37] *Edwards IR, et al. Effective risk communication in pharmacovigilance. Drug Saf. 2012;35:807–815.*
[38] *European Medicines Agency. Pharmacovigilance Inspections: A Practical Guide. EMA; 2018.*
[39] *Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–1259.*
[40] *Harpaz R, et al. Performance of pharmacovigilance signal-detection algorithms. Clin Pharmacol Ther. 2012;91:1014–1021.*
[41] *Sherman RE, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375:2293–2297.*
[42] *Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics. JAMA. 2001;286:2270–2279.*
[43] *Inácio P, Cavaco A. Patient reporting of adverse drug reactions. Drug Saf. 2012;35:409–427.*
[44] *Free C, et al. Effectiveness of mobile-health technologies. PLoS Med. 2013;10:e1001363.*
[45] *International Council for Harmonisation (ICH).* Pharmacovigilance Planning (E2E). *ICH; 2004.*